Ocular Therapeutix Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	51.95	63.72	58.44	51.49	43.52
Revenue Growth (YoY)	-18.47%	9.03%	13.49%	18.32%	150.08%
Cost of Revenue	6.57	5.63	5.28	4.54	4.41
Gross Profit	45.38	58.1	53.16	46.95	39.12
Selling, General & Admin	118.3	102.24	74.49	72.15	67.07
Research & Development	197.1	127.64	61.06	53.46	50.08
Total Operating Expenses	315.39	229.88	135.54	125.61	117.15
Operating Income	-270.02	-171.78	-82.38	-78.65	-78.04
Interest Income	18.36	20.28	3.98	0.8	0.03
Interest Expense	-11.84	-13.58	-11.34	-7.02	-6.67
Other Non-Operating Income (Expense)	-2.44	-28.43	9	13.84	78.12
Total Non-Operating Income (Expense)	4.08	-21.73	1.65	7.62	71.48
Pretax Income	-265.94	-193.51	-80.74	-71.04	-6.55
Net Income	-265.94	-193.51	-80.74	-71.04	-6.55
Net Income to Common	-265.94	-193.51	-80.74	-71.04	-6.55
Shares Outstanding (Basic)	187	158	80	77	76
Shares Outstanding (Diluted)	187	158	86	83	82
Shares Change (YoY)	18.31%	84.90%	3.57%	0.59%	35.24%
EPS (Basic)	-1.42	-1.22	-1.01	-0.92	-0.09
EPS (Diluted)	-1.42	-1.22	-1.02	-0.97	-0.98
Shares Outstanding	215.93	157.75	114.96	77.2	76.73
Free Cash Flow	-216.89	-135.97	-76.32	-63.32	-66.74
Free Cash Flow Per Share	-1.16	-0.86	-0.89	-0.77	-0.81
Gross Margin	87.35%	91.17%	90.96%	91.18%	89.88%
Operating Margin	-519.75%	-269.57%	-140.96%	-152.74%	-179.31%
Profit Margin	-511.90%	-303.67%	-138.15%	-137.95%	-15.06%
FCF Margin	-417.50%	-213.37%	-130.59%	-122.96%	-153.36%
EBITDA	-265.69	-168	-79.4	-76.55	-75.62
EBITDA Margin	-511.43%	-263.63%	-135.86%	-148.65%	-173.74%
EBIT	-270.02	-171.78	-82.38	-78.65	-78.04
EBIT Margin	-519.75%	-269.57%	-140.96%	-152.74%	-179.31%

Updated Feb 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q